Serotonin reuptake inhibitors are among the most prescribed medicines in the world, and sexual side effects are one of the most common reasons people stop taking them. They are also among the least likely to be asked about. In the largest prospective study of the question, 1,022 outpatients whose sexual function was normal before treatment were interviewed with a questionnaire that asked specifically about libido, orgasm, ejaculation and erection: 59.1% developed some form of sexual dysfunction (Montejo et al., 2001).

Studies that simply waited for patients to mention it reported far lower numbers. That gap — between asking and not asking — explains most of the confusion around this side effect, and it is why "my doctor never warned me" and "it affects a majority of patients" can both be true.

This article covers which drugs are most likely to affect orgasm, why orgasm is hit harder than desire, how to tell a drug effect from an ordinary run of difficult weeks, and where the evidence is genuinely uncertain. It is not medical advice, and nothing here is a reason to change how you take a prescription.

The class label is a poor guide

"SSRI" covers drugs with meaningfully different effects on sexual function, and averages hide that. A meta-analysis that included only studies where sexual function was asked about directly, in patients with no prior difficulties, found treatment-emergent sexual dysfunction in 25.8% to 80.3% of patients depending on the drug (Serretti & Chiesa, 2009).

In that analysis, ranked from most to least impact, the drugs were sertraline, venlafaxine, citalopram, paroxetine, fluoxetine, imipramine, phenelzine, duloxetine, escitalopram and fluvoxamine. A separate cross-sectional study of 6,297 patients across 1,101 primary care clinics put bupropion and nefazodone lowest, at roughly 22–28%, and SSRIs, mirtazapine and venlafaxine extended-release higher, at 36–43% (Clayton et al., 2002).

Two things follow from that. First, the range within the SSRI family is wide enough that "SSRIs cause sexual dysfunction" is too blunt to be useful. Second, several antidepressants are comparably effective to SSRIs (Cipriani et al., 2018), which is why "which drug" is a genuine question rather than a fixed cost of treatment.

Why orgasm, specifically

Sexual response is not one thing, and antidepressants do not affect its parts equally. Serotonin is involved in the spinal reflex that produces orgasm, which is why drugs that increase serotonin signalling tend to slow it down or blunt it:

  • Delayed orgasm. The most characteristic effect of serotonergic antidepressants — orgasm still happens, but takes substantially longer.
  • Muted or absent orgasm. Reduced intensity, or orgasm becoming unreliable or not arriving at all.
  • Reduced desire. Wanting sex less often, independent of whether the mechanics still work.
  • Reduced arousal. Slower or weaker physical response, even when desire is intact.

These map onto separate phases, and a drug can affect one while leaving others alone. That matters practically: "my libido is fine but I can't finish" is a recognisable, specific pattern — not a contradiction, and not something you are imagining.

It is also why a single question like "any sexual side effects?" tends to miss things. The honest answer is often "some, but not the part you asked about".

Why the leaflet understates it

The rates printed in product information come largely from trials that recorded side effects people reported spontaneously. Montejo's study compared that approach with a targeted questionnaire and found the difference was not subtle — which is why the published incidence figures for this side effect are widely considered to be understated (Rothmore, 2020).

Clayton's study made the same point from the other direction: it compared what physicians believed their patients were experiencing with what patients reported on a questionnaire, and the two did not match.

Timing, dose, and the possibility that it eases

Sexual side effects typically appear within the first weeks of starting or increasing a dose, alongside the therapeutic effect. Some people find they partially adapt over the first few months; others do not. Dose matters, and so does the specific drug — the differences between agents are large enough that they are usually worth more attention than the class label.

One important confounder: depression itself reduces sexual interest and function. Untreated, it lowers desire, enjoyment and sometimes orgasm, so a change after starting treatment can be the drug, the illness receding, the illness itself, or ordinary life. Teasing those apart from memory alone is hard, which is the argument for writing things down rather than reconstructing them later.

Post-SSRI sexual dysfunction

In a small number of people, sexual side effects persist after the antidepressant is stopped — a condition now called post-SSRI sexual dysfunction, or PSSD. The European Medicines Agency concluded that PSSD is a medical condition that can persist after discontinuation of SSRIs and SNRIs, and it is generally described as rare (Peleg et al., 2022; Rothmore, 2020).

The honest summary is that this exists, it is uncommon, and it is not a reason to avoid treatment you need. It is a reason not to dismiss a persistent change as something you should just live with. If sexual function has not returned well after stopping, that is worth raising with a clinician rather than waiting it out quietly.

How to tell what is actually happening

The practical problem is not knowing that SSRIs can affect orgasm — it is knowing whether they are affecting yours, by how much, and whether the picture is changing. Four things make that answerable:

  • A baseline. What was normal for you before the change, in rough numbers rather than impressions.
  • A date. When the dose started or changed, so the before and after have an edge rather than blurring together.
  • A consistent measure. The same question answered the same way, so the answers are comparable.
  • Enough of them. Single sessions are noise. A month either side of a change is a pattern.

That is essentially a tracking problem, and it is the one thing you can do without a prescription. It also produces something concretely useful at an appointment: "orgasm became delayed and less intense within two weeks of the dose increase, and it has stayed that way for six weeks" is a different conversation from "I think it might be worse".

Orgasmly records intensity, method and timing per session and can plot a medication period against what came before and after it. If you want the wider picture, the companion article on medication and orgasm covers non-psychiatric drugs, and bupropion covers the antidepressant most often chosen when this side effect is the problem.

The short version

Sexual side effects from SSRIs and SNRIs are common, under-reported, and concentrated in the orgasm phase more than in desire. The rate depends heavily on the specific drug — the spread within the class is roughly threefold — and on whether anyone asked you about it. Most of it is reversible, a small amount is not, and the useful thing you can do is establish what your normal looks like before and after a change so the question "is this the medication?" has an answer.

Sources

  1. Montejo, A. L., Llorca, G., Izquierdo, J. A., & Rico-Villademoros, F. (2001). Incidence of Sexual Dysfunction Associated with Antidepressant Agents: A Prospective Multicenter Study of 1022 Outpatients. Journal of Clinical Psychiatry, 62(Suppl 3), 10–21. (Enrolled only patients with previously normal sexual function; used a questionnaire that asked directly about libido, orgasm, ejaculation and erection.) https://pubmed.ncbi.nlm.nih.gov/11229449/
  2. Serretti, A., & Chiesa, A. (2009). Treatment-Emergent Sexual Dysfunction Related to Antidepressants: A Meta-Analysis. Journal of Clinical Psychopharmacology, 29(3), 259–266. (Restricted to studies using direct inquiry and specific questionnaires.) https://doi.org/10.1097/JCP.0b013e3181a5233f
  3. Clayton, A. H., Pradko, J. F., Croft, H. A., et al. (2002). Prevalence of Sexual Dysfunction Among Newer Antidepressants. Journal of Clinical Psychiatry, 63(4), 357–366. (Cross-sectional study across 1,101 US primary care clinics; 4,534 women and 1,763 men on antidepressant monotherapy.) https://doi.org/10.4088/jcp.v63n0414
  4. Rothmore, J. (2020). Antidepressant-Induced Sexual Dysfunction. Medical Journal of Australia, 212(7), 329–334. (Clinical review covering assessment and management, including post-SSRI sexual dysfunction.) https://doi.org/10.5694/mja2.50522
  5. Peleg, L. C., Rabinovitch, D., Lavie, Y., et al. (2022). Post-SSRI Sexual Dysfunction (PSSD): Biological Plausibility, Symptoms, Diagnosis, and Presumed Risk Factors. Sexual Medicine Reviews, 10(1), 91–98. https://doi.org/10.1016/j.sxmr.2021.07.001
  6. Cipriani, A., Furukawa, T. A., Salanti, G., et al. (2018). Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults with Major Depressive Disorder: A Systematic Review and Network Meta-Analysis. The Lancet, 391(10128), 1357–1366. (522 trials, 116,477 participants. Used as the reference for which drugs are comparably effective, so switching is a real option.) https://doi.org/10.1016/S0140-6736(17)32802-7